Plus Therapeutics
PSTV
20 hedge funds and large institutions have $1.58M invested in Plus Therapeutics in 2022 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 6 reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
11% more funds holding
Funds holding: 18 → 20 (+2)
0% less ownership
Funds ownership: 0.04% → 0.04% (-0%)
18% less capital invested
Capital invested by funds: $1.93M → $1.58M (-$353K)
67% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$141K |
| 2 |
TSS
Two Sigma Securities
New York
|
+$38.2K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$27.5K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$10K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$1.34K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
-$124K |
| 2 |
Morgan Stanley
New York
|
-$70.5K |
| 3 |
Renaissance Technologies
New York
|
-$18.1K |
| 4 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
-$8.93K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$6.25K |
PSTV Hedge Fund Activity: Q3 2022 in Review
20 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Plus Therapeutics (PSTV) for Q3 2022, worth a combined $1.58M — down 18% from $1.93M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new PSTV positions and 1 closed out — a net gain of 2 holders — while 2 added to existing stakes and 6 trimmed.
The largest buyer was Vanguard Group, adding an estimated $141K. The largest seller was Parkman Healthcare Partners, cutting an estimated $124K.
- 20 institutional investors held Plus Therapeutics (PSTV) as of Q3 2022, up from 18 in Q2 2022.
- Funds reported $1.58M of Plus Therapeutics stock for Q3 2022, down 18% quarter-over-quarter.
- 3 funds opened new Plus Therapeutics positions in Q3 2022 and 1 closed out, a net change of +2 holders.
- The largest Plus Therapeutics buyer in Q3 2022 was Vanguard Group, an estimated $141K added.
- The largest Plus Therapeutics seller in Q3 2022 was Parkman Healthcare Partners, an estimated $124K sold.
Based on aggregated 13F filings for Q3 2022.